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a b s t r a c t 
Background: The presence of co-morbidities, including underlying respiratory problems, has been identi- 
fied as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infec- 
tion in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with 
CF, their families, caregivers and clinical teams. 
Methods: Cases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the 
CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020. 
Results: Data on 105 children were collated and analysed. Median age of cases was ten years (interquar- 
tile range 6–15), 54% were male and median percentage predicted forced expiratory volume in one second 
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was 94% (interquartile range 79–104). The majority (71%) of children were managed in the community 
during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen 
and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antivi- 
ral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had 
lower lung function and reduced body mass index Z-scores. One child died six weeks after testing posi- 
tive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease. 
Conclusions: SARS-CoV-2 infection in children with CF is usually associated with a mild illness in those 
who do not have pre-existing severe lung disease. 
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
The COVID-19 global pandemic caused by the severe acute res- 
piratory syndrome coronavirus 2 (SARS-CoV-2) has had a profound 
impact around the world [1,2] . A spectrum of respiratory disease 
has been observed ranging from mild (asymptomatic or flu-like 
symptoms) to severe (acute respiratory distress syndrome, fulmi- 
nant respiratory failure and high mortality) [2] . Various extrapul- 
monary manifestations of COVID-19 have also been recognised that 
include haematological, renal, gastrointestinal, cardiovascular and 
neuropsychiatric problems [3] . The presence of co-morbidities, in- 
cluding underlying respiratory problems, has been identified as a 
key risk factor for severe disease along with older age [4–6] . Cur- 
rent reports suggest that SARS-CoV-2 infection is generally less se- 
vere in children than in adults [6,7] . Most children remain asymp- 
tomatic or experience only mild symptoms during infection [5,6] . 
Notably, a rare multisystem inflammatory syndrome in association 
with SARS-CoV-2 infection has been described in a small subset of 
children and young people [8] . 
In view of the severity of COVID-19 and high transmissibility 
of SARS-CoV-2, advice was issued in many countries at the out- 
set of the global pandemic for people with cystic fibrosis (CF) and 
their families to strictly isolate to reduce the chances of contract- 
ing the virus [9,10] . Respiratory viruses are known to cause pul- 
monary exacerbations and substantial morbidity in people with CF 
[11] . There is some evidence to suggest that the innate immune 
response of CF airway epithelia to respiratory viruses is impaired 
[12–14] . During the 2009 influenza A (H1N1) pandemic infection 
was associated with substantial morbidity in people with CF and a 
high mortality rate in those admitted to intensive care [15,16] . Con- 
versely, other aspects of CF airway pathophysiology may mitigate 
against severe COVID-19 disease [17,18] . CF airway epithelial cells 
may be less susceptible to coronavirus infection due to altered in- 
tracellular processes involved in host defence and viral replication, 
for example autophagy, unfolded protein response and NOD-, LRR- 
and pyrin domain-containing protein 3 inflammasome [17] . SARS- 
CoV-2 has also been shown to mimic the proteolytic activation of 
the epithelial sodium channel by furin cleavage [19] . This provides 
a potential mechanism for reduced entry of SARS-CoV-2 in to CF 
airway epithelial cells. 
Detailed information on the clinical course of COVID-19 in chil- 
dren with CF is lacking and represents an important knowledge 
gap. There are two individual case reports in children with varying 
levels of pre-existing lung disease [20,21] . The first involves a nine- 
year-old girl with severe CF lung disease who tested positive for 
SARS-CoV-2 at the same time as her father was hospitalised with 
COVID-19 [21] . This illness was associated with minor haemopty- 
sis but no other change in her respiratory status [21] . The second 
case report describes asymptomatic infection in a one-month old 
infant with CF identified by contact tracing [20] . In May 2020 the 
CF Registry Global Harmonization Group published an initial report 
of COVID-19 cases that included a 15 year old child [22] . A range 
of clinical severity was described in this series with the majority 
of adult cases being mild or moderate [22] . An updated report in- 
cluding cases up to June 13 2020, was published in November 2020 
and recorded 7 deaths [23] . This latest report included 53 children 
aged < 18 years in the dataset but there was no specific analysis of 
this group. 
Increased understanding about SARS-CoV-2 infection in the 
paediatric age group is crucial to provide accurate and balanced 
advice that will keep children with CF safe, and recognise the rel- 
ative risks, but also enable them to lead their lives in the most 
fulfilling way possible during the ongoing pandemic. This is partic- 
ularly important given the associated disadvantages and substan- 
tial negative effects on quality of life, mental health, schooling and 
delivery of healthcare of strict isolation measures [8,24–28] . Here 
we detail the clinical course and outcomes of SARS-CoV-2 infection 
in 105 children with CF collated by an international collaborative 
group and representing the only large dataset thus far reported. 
2. Methods 
2.1. Study design 
The ‘Cystic Fibrosis Registry Global Harmonization Group’ is a 
collaborative international group of patient registries. At the start 
of the COVID-19 pandemic the group set up fortnightly videocon- 
ferences to share experience. Nineteen countries participated in 
the study that ran between 1 February and 7 August 2020. 
Children were defined as individuals aged less than 18 years. 
Cases were included if they had a confirmed diagnosis of CF and 
were either diagnosed with SARS-CoV-2 infection via a polymerase 
chain reaction (PCR) test on a respiratory sample or a clinical diag- 
nosis of COVID-19 was made in a hospital setting. Cases reported 
via antibody testing alone or self-reporting were excluded. 
CF centres that had reported SARS-CoV-2 cases to their registry 
were asked to complete an anonymised data collection form and a 
designated country representative then collated all national cases 
for the study. Representatives provided the most comprehensive 
data available on each individual case. Data collected included de- 
tails of the clinical presentation, management and outcome along 
with relevant patient demographics, including cystic fibrosis trans- 
membrane conductance regulator ( CFTR ) genotype, body mass index 
(BMI), best percentage predicted forced expiratory volume in one 
second (ppFEV 1 ) in the 12 months prior to infection, usual medi- 
cations, pre-existing CF-related complications, respiratory microbi- 
ology and transplant status. 
2.2. Data analysis 
The United Kingdom CF Registry team and the Children’s Res- 
piratory Group from Newcastle University performed analyses of 
pooled cases submitted by participating countries. Data were re- 
garded as missing where specific information was not available 
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at the time of data collection. Results were summarised in tables 
as numbers and proportions for categorical data and median val- 
ues with interquartile ranges for continuous data. For categories 
where some data were missing, the number of cases where data 
were available was cited in the table. BMI Z-scores adjusted for 
age and sex were calculated using the World Health Organisation 
Child Growth Standards [29,30] . As age was recorded in years, age 
+ 0 • 5 years was used in this calculation for each child. Normality of 
data was assessed with Shapiro Wilk testing. Subgroup analyses of 
hospitalised and non-hospitalised cases were performed using ei- 
ther Mann-Whitney test for continuous data or Fisher’s exact test 
for categorical data using GraphPad Prism software (version 8 • 4 • 3). 
P values of < 0 • 05 were considered statistically significant. 
2.3. Information governance and ethics 
Each participating country was responsible for ensuring re- 
search ethics or institutional approvals were in place for this work 
as per their individual patient registries. 
2.4. Role of the funding source 
The funding source had no involvement in the collection, analy- 
sis or interpretation of data, writing or decision to submit for pub- 
lication. 
3. Results 
Data on 105 cases of SARS-CoV-2 infection in children with CF 
were analysed. From the 19 countries that make up the CF Registry 
Global Harmonization Group, 13 reported cases (Argentina, Brazil, 
Chile, France, Germany, Italy, Russia, South Africa, Spain, Sweden, 
Switzerland, United Kingdom and United States of America). Case 
numbers for individual countries have not been specified to main- 
tain confidentiality. 
Details of the method of diagnosis of COVID-19 were available 
in 96 children. This was via a positive PCR test for SARS-CoV-2 
on a respiratory sample in 95 children and by clinical diagnosis 
of COVID-19 in a hospital setting in one. 
3.1. Case demographics 
Case demographics and features of pre-existing CF disease in 
the cohort are summarised in Table 1 . Median age was ten years 
and 54% were male. Forty-three (41%) children were homozygous 
for the F508del CFTR mutation. Median best ppFEV 1 within 12 
months prior to infection for those over the age of five years was 
94%. Thirty-one had Pseudomonas aeruginosa respiratory infection 
and 31 were on long-term azithromycin treatment. Fifty children 
were on a CFTR modulator. None were on an active list awaiting 
transplantation and two children were post-transplant (one lung 
and one liver). 
3.2. Symptoms, acute treatments, management and outcome 
A summary of the symptomatology, management and treat- 
ment of cases is provided in Table 2 . Where relevant data were 
available, just over a quarter of children were asymptomatic. In 
those with symptoms, fever (73%) and altered cough (72%) were 
the most common features with 23% experiencing gastrointestinal 
symptoms. Other less frequently reported symptoms were fatigue, 
headache and rhinitis each reported in two cases and loss of smell 
and taste experienced by one child. 
Varied levels of care were required with 71% of children be- 
ing managed in the community and the remainder admitted to 
Table 1 
Patient demographics and pre-existing cystic fibrosis disease. 
Sex n = 105 
Male 57 (54%) 
Female 48 (46%) 
Age: median years (IQR) n = 105 10 (6–15) 
0–1 year 11 (10%) 
2–4 year 7 (7%) 
5–12 year 43 (41%) 
13–18 year 44 (42%) 
Body mass index Z-score: median (IQR) n = 84 0 • 08 ( −0 • 81–0 • 87) 
CFTR Genotype n = 104 
Homozygous F508del 43 (41%) 
Heterozygous F508del 32 (31%) 
Other 29 (28%) 
Pancreatic insufficient n = 100 84 (84%) 
CF related diabetes n = 100 9 (9%) 
Lung function n = 82 
Best ppFEV1: median (IQR) 94 (79–104) 
> 70 67 (82%) 
40–70 12 (14 • 5%) 
< 40 3 (3 • 5%) 
Respiratory microbiology n = 96 
No positive microbiology 20 (21%) 
Staphylococcus aureus 65 (68%) 
Pseudomonas aeruginosa 31 (32%) 
Haemophilus influenzae 10 (10%) 
Nontuberculous mycobacteria 7 (7%) 
Aspergillus species 1 (1%) 
Allergic bronchopulmonary aspergillosis n = 101 8 (8%) 
CFTR modulator therapy n = 83 50 (60%) 
Chronic azithromycin treatment n = 55 31 (56%) 
Transplant history 
Solid organ recipient n = 105 2 (2%) 
Awaiting transplant n = 95 0 (0%) 
COVID-19 diagnosis n = 96 
Positive respiratory sample PCR 95 (99%) 
Clinical diagnosis in hospital setting 1 (1%) 
The proportion of each value was calculated from the non-missing data in each 
group as depicted by n. Abbreviations: CFTR: cystic fibrosis transmembrane 
conductance regulator; ppFEV1: percent predicted forced expiratory volume in 
one second; IQR: interquartile range; PCR: polymerase chain reaction. 
Table 2 
Symptomatology, treatment and management. 
Symptoms 
Asymptomatic n = 89 26 (29%) 
Fever n = 63 46 (73%) 
Altered cough n = 53 38 (72%) 
Dyspnoea n = 44 13 (30%) 
Gastrointestinal n = 39 9 (23%) 
Myalgia n = 37 7 (19%) 
Level of care 
Community n = 82 58 (71%) 
Hospital admission n = 82 24 (29%) 
Intensive care n = 83 1 (1%) 
Respiratory support in hospitalised patients 
New supplemental oxygen n = 21 6 (29%) 
New non-invasive ventilation n = 20 2 (10%) 
Invasive ventilation n = 20 1 (5%) 
Additional medical management 
New antibiotic therapy 
- Oral antibiotics n = 43 16 (37%) 
- Intravenous antibiotics in hospital n = 39 14 (36%) 
- Intravenous antibiotics at home n = 37 4 (11%) 
Experimental antiviral therapy n = 36 5 (14%) 
Ritonavir/lopinavir 3 (8%) 
Interferon therapy 1 (3%) 
Ivermectin 1 (3%) 
The proportion of each value was calculated from the non- 
missing data in each group as depicted by n . 
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Table 3 
Association of CF disease characteristics and hospitalisation for COVID-19. 
Hospitalised n = 24 Not Hospitalised n = 58 P value 
Sex 0 • 808 † 
Male 12 (27%) 32 (73%) 
Female 12 (32%) 26 (68%) 
Age: median (IQR) 14 (9–15) 9 (5–15) 0 • 099 ∗
0–1 year n = 9 2 (22%) 7 (78%) 
2–4 year n = 6 0 (0%) 6 (100%) 
5–12 year n = 29 7 (24%) 22 (76%) 
13–18 year n = 38 15 (39%) 23 (61%) 
Body mass index Z-score: median (IQR) n = 61 −0 • 55 ( −1 • 46- −0 • 06) 0 • 32 ( −0 • 55–0 • 92) 0 • 015 ∗
Genotype 
Homozygous F508del n = 36 8 (22%) 28 (78%) 0 • 222 † 
Heterozygous F508del n = 23 7 (30%) 16 (70%) > 0 • 999 † 
Other n = 22 9 (41%) 13 (59%) 0 • 274 † 
Not known n = 1 0 (0%) 1 (2%) 
Pancreatic status 0 • 029 † 
Insufficient n = 71 24 (34%) 47 (66%) 
Sufficient n = 11 0 (0%) 11 (100%) 
CF related diabetes 0 • 116 † 
Yes n = 9 5 (56%) 4 (44%) 
No n = 73 19 (26%) 54 (74%) 
Best ppFEV1 median (IQR) 73 (48–94) 97 (86–108) 0 • 002 ∗
> 70 n = 50 11 (22%) 39 (78%) 
40–70 n = 12 8 (67%) 4 (33%) 
< 40 n = 3 2 (67%) 1 (33%) 
Allergic bronchopulmonary aspergillosis n = 8 5 (63%) 3 (37%) - # 
CFTR modulator therapy 0 • 007 † 
No modulator treatment n = 30 14 (47%) 16 (53%) 
Modulator treatment n = 40 6 (15%) 34 (85%) 
The proportion of each value is calculated from the non-missing data in each group as depicted by n . 
† Statistical analysis performed using Fisher’s exact test. 
∗ statistical analysis performed using Mann-Whitney test. 
# no statistical testing performed on allergic bronchopulmonary aspergillosis group due to small numbers. Abbrevia- 
tions: CFTR: cystic fibrosis transmembrane conductance regulator; ppFEV1: percent predicted forced expiratory volume 
in one second; IQR: interquartile range. 
hospital. One child was admitted to intensive care six weeks af- 
ter acute SARS-CoV-2 infection. A range of treatments were used, 
these included oral (37%) or intravenous (46%) antibiotics with the 
majority of intravenous antibiotics being administered in hospital. 
Four children received azithromycin acutely, five antiviral medica- 
tions and one additional corticosteroids. Of those who were hos- 
pitalised, six required new supplementary oxygen therapy, two re- 
quired non-invasive ventilation and one invasive ventilation. None 
were supported with extracorporeal membrane oxygenation. No 
children received experimental treatments for COVID-19 other than 
azithromycin, interferon or corticosteroids. 
At the time of writing, only two cases were described as un- 
resolved, however no formal follow up information is available at 
this stage. Both solid organ transplant recipients recovered from 
COVID-19. There were no deaths directly attributed to COVID- 
19. One child died approximately six weeks after testing posi- 
tive for SARS-CoV-2. This child had been unwell with deteriorat- 
ing health during the preceding year including several severe pul- 
monary exacerbations requiring intensive care admission. During 
the COVID-19 illness the child was treated with intravenous antibi- 
otics, lopinavir/ritonavir and managed in a ward setting. The child 
recovered from that acute illness and became negative on repeat 
SARS-CoV-2 testing. However, six weeks later the child experienced 
a further severe pulmonary exacerbation requiring admission to in- 
tensive care, intubation and mechanical ventilation, and sadly died 
from respiratory failure. 
3.3. Characteristics associated with hospitalisation for COVID-19 
illness 
The characteristics of children admitted to hospital with COVID- 
19 were compared with those managed in the community in an 
exploratory analysis using hospitalisation as the best available sur- 
rogate of disease severity in our dataset ( Table 3 ). There were no 
statistically significant differences between sex and CFTR genotype 
in each group. Although the median age was higher in children 
admitted to hospital, this was not statistically significant. Median 
BMI Z-score was lower in children admitted to hospital. No pancre- 
atic sufficient children were admitted to hospital with COVID-19. 
Around half of children with CF-related diabetes were admitted to 
hospital. Children admitted had a lower median ppFEV 1 (73%) than 
those managed in the community (97%). Significantly fewer chil- 
dren were hospitalised who were receiving CFTR modulator ther- 
apy, however, it should be noted that access to modulator drugs 
varied between countries. 
4. Discussion 
We describe to our knowledge the first case series of SARS-CoV- 
2 infection in children with CF. Information was captured on 105 
children across 13 countries with a spread of ages ranging from 
infants through to adolescents. Some of these cases were included 
within a predominantly adult series, where, crucially, no analysis 
of the paediatric age group was performed [23] . Specific data on 
children are urgently required to inform decisions around educa- 
tion for example [28] . The majority of children experienced a rel- 
atively mild illness. Over two thirds were managed in the com- 
munity and of the 24 admitted to hospital six required a period 
of supplementary low flow oxygen and two needed non-invasive 
ventilation during their admission. One child was admitted to in- 
tensive care, however, this case appears to have been exceptional 
as discussed below. Two children at the endpoint of data collec- 
tion were in a recovery phase with the remainder having made a 
full recovery. 
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This is a diverse cohort from multiple countries and in-depth 
comparisons as to how representative the cohort is of children 
with CF worldwide in general are not possible. The median best 
ppFEV 1 in the preceding year was in the normal range at 94%. 
This level of lung function is comparable with the median ppFEV 1 
for those aged < 18 years in 2019 registry reports from the United 
Kingdom (89.5%) and United States (95%) [31,32] . Around a third 
had P. aeruginosa infection. This compares to around 25% of chil- 
dren aged < 18 years isolating P. aeruginosa in the last 12 months 
in the 2019 United States CF and United Kingdom registries [31,32] . 
Due to the international nature of the cohort, availability of CFTR 
modulator therapy varied between individual countries, with 60% 
receiving a CFTR modulator. 
The distribution of symptoms associated with COVID-19 was 
similar to those reported in other paediatric, non-CF, cohort studies 
[5–7] . Interestingly, just over a quarter were asymptomatic at the 
time of testing positive for SARS-CoV-2. Many of these children un- 
derwent testing as part of the process of an elective admission to 
hospital during the pandemic or via contact tracing. Although this 
is unlikely to reflect the true asymptomatic rate, it is in line with 
other multinational paediatric observational studies [5,6] . 
Most children were treated with oral or intravenous antibiotics 
as is standard practice for any CF respiratory exacerbation [33] . A 
minority received antiviral medications and none received experi- 
mental treatments for COVID-19 other than azithromycin or inter- 
feron. This may reflect the generally low severity of acute illness 
in the cohort. Data showing some clinical benefit from remdesivir 
in adults with COVID-19 were published in September and October 
2020 after the census period of this study [34–36] . Only one child 
was recorded as having received additional corticosteroid treat- 
ment although the RECOVERY collaborative group only published 
the results of dexamethasone in hospitalised adult patients in mid- 
July 2020 and the final date for inclusion of cases in this cohort 
was August 7 2020 [37] . 
Some studies have found that those with solid organ trans- 
plants are at an increased risk of severe COVID-19 [38] . In our 
case series, both children who had received solid organ transplants 
made a full recovery. A small number of adults with CF post-solid 
organ transplant have died from COVID-19 [23] . 
We compared the characteristics of children admitted to hos- 
pital with those managed in the community as the best available 
surrogate of COVID-19 disease severity in our dataset. Children ad- 
mitted to hospital had lower lung function, reduced BMI Z-scores 
and were less likely to be maintained on a CFTR modulator. No 
differences in gender were found. Importantly, these comparisons 
were performed with caution and are exploratory due to the rel- 
atively small overall numbers, prevalence of missing data, vari- 
able access to CFTR modulators internationally and the important 
caveat that some children were likely to have been tested for SARS- 
CoV-2 in association with a hospital admission for other reasons. 
There was one clear exception in the cases reported. A child, 
who had experienced a worrying clinical trajectory over the last 
year with respect to their underlying CF disease, developed a se- 
vere pulmonary exacerbation six weeks after testing positive for 
SARS-CoV-2. The clinical team involved did not consider this fi- 
nal illness to be related to the SARS-CoV-2 infection or the paedi- 
atric multisystem inflammatory syndrome that has been described 
in temporal association with COVID-19 [8] . 
This dataset was collated during a global pandemic involving 
multiple national patient registries and there are inevitable lim- 
itations. There are missing values within the dataset partly due 
to variation in data collection methods between individual reg- 
istries. This highlights the importance of ongoing work towards 
registry harmonisation to facilitate and optimise collaborative re- 
porting [39,40] . Each national registry provided the full data that 
were available to them about each case. A pragmatic decision was 
made to not go back to individual clinical teams to request missing 
data. This would be a hugely time consuming and labour-intensive 
process across 13 countries and would ultimately delay the pub- 
lication of urgently required information about the overall clinical 
course of children with CF who have been infected with SARS-CoV- 
2. The method of case capture was not exhaustive and was de- 
pendant on reporting. Furthermore, at the time of writing formal 
follow up data were not available. The total paediatric population 
incorporated within the patient registries involved is estimated to 
be around 40,0 0 0 children. It is likely that the true number of 
children with CF infected with SARS-CoV-2 is greater than those 
captured in our study due to differences in testing protocols inter- 
nationally and variation in false negative rates of COVID-19 tests. 
Pragmatically, cases were included if children were symptomatic 
and the clinical team saw signs and symptoms that are character- 
istically related to COVID-19 [41] . However, only a single case was 
included on this basis with the remainder having a positive PCR 
test. 
A major strength of this work is that it is the only large detailed 
case series of COVID-19 specifically focussing on children with CF. 
This study provides valuable information that will guide children 
with CF and their families and clinical teams. In summary, our 
findings suggest that SARS-CoV-2 infection in children with CF is 
usually associated with a mild illness in those who do not have 
pre-existing severe lung disease. It remains important, however in 
our opinion, that children with CF are considered a priority for ac- 
cess to vaccination programmes for SARS-CoV-2 once regulatory 
approvals are in place. Follow up of children with CF who have 
experienced infection with SARS-CoV-2 will be important to assess 
for the development of any long term complications or impact on 
lung function. 
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